|
| Webinar: Improving the discovery of novel drugs with artificial intelligence Thursday, February 3, 2022 | 2pm ET / 11am PT This webinar will cover the newest and most innovative AI solutions that have been developed for the life sciences industry. Topics include how AI can be used to improve the ability to predict which compounds are likely to make it to late-stage trials, best practices for choosing and partnering with technology developers to maximize the benefits of AI in drug development, and more. Register now. |
WELCOME TO FIERCE LIFE SCIENCES WEEKLY DIGEST Another (virtual) JPM week has come and gone. Bayer inked a CRISPR deal worth up to $1 billion in biobucks with Doudna’s Mammoth Biosciences, while Sanofi outlined its plans to build Big Pharma’s strongest immunology business. Meanwhile, Novavax has set its sights on establishing itself as a global vaccine player in 2022, and Dexcom provided a look at new blood sugar data from the next-generation of its mainstay diabetes sensor. Those stories, plus roundups of all the news from the J.P. Morgan Healthcare Conference, follow below. | |
|
Featured Story | By Fraiser Kansteiner Novavax’s COVID-19 vaccine is destined for the global market, where the company expects demand to play out across all three chief areas: primary vaccination, boosters and the pediatric market, Silvia Taylor, senior vice president, global corporate affairs and investor relations at Novavax, said in an interview on the sidelines of the J.P. Morgan Healthcare Conference. read more |
| |
|---|
|
Top Stories Of The Week By Angus Liu Bayer is adding more building blocks to its cell and gene therapy ambition by tapping Mammoth Biosciences' CRISPR gene editing toolbox in a strategic collaboration with $40 million upfront and potentially worth over $1 billion. read more By Conor Hale The new G7 wearable glucose sensor "very comfortably meets" the FDA’s accuracy requirements, according to Dexcom CEO Kevin Sayer. read more By Eric Sagonowsky Sanofi has been no stranger to the biopharma dealmaking circuit under CEO Paul Hudson, and last year it inked a handful of biotech buyouts for mRNA, an FDA-approved transplant med and more. Now, when asked about the company's business development plans going forward, Sanofi's CFO said the company thinks it can build an industry-leading immunology franchise. read more By Kyle LaHucik Sarepta Therapeutics will ask the FDA to approve its gene therapy for Duchenne muscular dystrophy next year if the data from a pivotal trial is consistent with existing evidence, the biotech said at JPM 2022 on Monday. The biotech, with three approved DMD meds, said its gene therapy helped kids improve their motor skills. read more By Ben Adams,Annalee Armstrong,Conor Hale,Kyle LaHucik Join us for a rolling look at the top life sciences news coming out of this year's virtual J.P. Morgan Healthcare Conference. read more By Eric Sagonowsky,Fraiser Kansteiner,Kevin Dunleavy,Angus Liu Boot up those computers and get your J.P. Morgan healthcare conference meeting links ready, because it's set to be a week full of biopharma action. read more By Fraiser Kansteiner Rather than 75 years, it will now take about eight months for the FDA to make public the information it used to license Pfizer and BioNTech’s COVID-19 vaccine—provided the regulator can keep up with the new schedule. read more By Nick Paul Taylor AstraZeneca is stepping up its pursuit of a rare disease market targeted by Alnylam and Pfizer. Having entered the ATTR space through its takeover of Alexion, AstraZeneca is paying $30 million for worldwide rights to Neurimmune’s NI006 in its second deal in the indication in quick succession. read more By Ben Adams Pfizer is culling hundreds of sales reps in the U.S. as the company shifts into digital drive as the pandemic pushed away in-person meetings. read more By Kyle LaHucik A hormone produced in fat tissue could pave the way for new treatments for diabetes and could overcome the challenges of insulin resistance. The molecule, dubbed FGF1, could help lower blood glucose in people who are resistant to insulin, researchers at Salk Institute reported in the journal Cell Metabolism. read more By Fraiser Kansteiner Catalent received an FDA write-up for its syringe filling facility in Belgium, BioProcess International reports, adding that it is "allegedly" the culprit behind supply challenges for Novo Nordisk’s obesity med Wegovy. read more Resources Sponsored by: WIRB-Copernicus Group Sites receiving augmentation support enroll more than 30,000 patients in just over three months. See how additional site resources can make a difference. Sponsored by: Thermo Fisher Scientific Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific Sponsored by: Thermo Fisher Scientific A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants. Sponsored by: IQVIA Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making. Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. | 